Review articleImmunotherapy for castration-resistant prostate cancer: Progress and new paradigms☆,☆☆
Keywords
Cited by (0)
- ☆
The authors take full responsibility for the content of this publication and confirm that it reflects their viewpoint and medical expertise. The authors also wish to acknowledge Rebecca Turner, StemScientific, funded by Bristol-Myers Squibb, for providing writing and editorial support. Neither Bristol-Myers Squibb nor StemScientific influenced the content of the manuscript, nor did the authors receive financial compensation for authoring the manuscript.
- ☆☆
D.Q. discloses payment for scientific advisory board participation from Amgen, Astellas, Bayer Healthcare, BMS, Dendreon, Fresenius Kabi, Millennium Takeda, Novartis, Janssen, Medivation, and Teva. He has received clinical trial funding from the National Cancer Institute, Millennium Takeda, GlaxoSmithKline, and Sanofi-Aventis. N.S. discloses involvement in research or consultancy for Algeta, Amgen, Bayer, Dendreon, Genomic Health, Myriad, Janssen, Medivation, Pfizer, and Sanofi-Aventis. S.E. discloses research finding from Astellas, AstraZeneca, and Takeda. K.F. discloses participation in advisory board or speaker for Dendreon, CureVac, Janssen, Astellas, Amgen, Bayer, Sanofi, Novartis, and Bristol-Myers Squibb.